---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-003063"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:17:03.170522+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nasdaq Panel grants CNS Pharmaceuticals extension to July 15, 2024 to regain listing compliance

## Summary
- Hearing held April 18, 2024; panel grants extension until July 15, 2024.
- Must demonstrate compliance with minimum bid price (Rule 5550(a)(2)) and stockholders' equity (Rule 5550(b)).
- Company intends to implement its plan to meet the milestones set by the Panel.
- Failure to comply by July 15 could result in delisting from Nasdaq.

## SEC filing metadata
- accession: 0001683168-24-003063
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824003063/0001683168-24-003063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824003063/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-003063
- JSON: https://secwatch.observer/filing/0001683168-24-003063.json
- Plain text: https://secwatch.observer/filing/0001683168-24-003063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.